Enliven Therapeutics Closes Merger with Imara and Private Placement of $165 Million
Combined company will be focused on advancing Enliven’s clinical-stage pipeline of precision oncology programs Shares to trade on Nasdaq under...
Clinical Trial
Shattuck Labs Reports Fourth-Quarter and Full-Year 2022 Financial Results and Provides Business Updates
– Initiated enrollment in Phase 1B clinical trial of SL-172154 in combination with mirvetuximab soravtansine in platinum-resistant ovarian cancer –...
Generation Bio Outlines 2023 Strategic Priorities and Reports Fourth Quarter and Full Year 2022 Financial Results
— Company expects to announce data for Factor VIII expression in non-human primates in 2023 — Strong cash balance of...
ABVC BioPharma Receives $3.175 Million Investment From The Lind Partners to Continue Clinical Trials
FREMONT, CA, Feb. 23, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire – ABVC BioPharma, Inc. (NASDAQ: ABVC), a clinical stage biopharmaceutical...
Codexis Reports Fourth Quarter and Fiscal Year 2022 Financial Results
Biotherapeutics Application of CodeEvolver® Validated by Recent Data Supporting the Potential for Three Upcoming Investigational New Drug Applications Cash Runway...
Relay Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Corporate Highlights
Advanced RLY-4008: Reported interim data with 88% overall response rate at pivotal dose and 63% across all doses in pan-FGFR...
Plus Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Business Highlights
Initiated ReSPECT-GBM Phase 2 and ReSPECT- LM Phase 1 trials for CNS cancers Awarded $17.6 million Cancer Prevention & Research...
Codexis and Nestlé Health Science Announce Interim Results from Phase 1 Clinical Trial of CDX-7108 for Exocrine Pancreatic Insufficiency
Interim Data from Phase 1 Proof-of-Concept Arm Indicates CDX-7108 Improves Lipid AbsorptionREDWOOD CITY, Calif., Feb. 23, 2023 (GLOBE NEWSWIRE) --...
Vir Biotechnology Provides Corporate Update and Reports Fourth Quarter and Full Year 2022 Financial Results
– Transformational year ahead with critical Phase 2 readouts expected for programs in hepatitis B, hepatitis D and influenza with...
Aerami Therapeutics Announces Expansion of the AER-901 (inhaled imatinib) Development Program in Pulmonary Hypertension Supported by Phase 1 Clinical Trial Data and Continued Progress
Expansion of the AER-901 development program to include pulmonary hypertension associated with interstitial lung disease (PH-ILD) builds on the company’s...
Biora Therapeutics Announces Bioavailability Results for Oral Delivery of GLP-1 Receptor Agonist
Preclinical data demonstrate potential to orally deliver peptides and monoclonal antibodies at bioavailability levels more than double the company’s current...
Predictive Oncology and Cvergenx announce partnership to develop the first-ever genomics-based approach to precision radiation therapy and drug discovery using artificial intelligence
EAGAN, Minn., Feb. 23, 2023 (GLOBE NEWSWIRE) -- Predictive Oncology Inc. (NASDAQ: POAI) and Cvergenx, Inc. today announced an agreement to...
BioCorRx Attended 4th Annual NIH HEAL Initiative Investigator Meeting; Shares Update on BICX104 Data
ANAHEIM, CA, Feb. 23, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire – BioCorRx Inc. (OTCQB: BICX) (the “Company”), a developer and...
uniQure Announces HOPE-B Clinical Trial Data Published in the New England Journal of Medicine, Demonstrating Durability and Other Benefits of HEMGENIX® (etranacogene dezaparvovec-drlb)
~ Data follow the historic approval of the first gene therapy for hemophilia B, which has been shown in clinical...
Ocean Biomedical (NASDAQ: OCEA) Celebrates Discovery of Bispecific Antibodies and Immune Checkpoint Inhibitors That Kill Glioblastoma Cells and Melanoma Cells, and Block the Metastasis of Malignant Melanoma Cells to the Lung by Over 90%
Providence, RI, Feb. 23, 2023 (GLOBE NEWSWIRE) -- As previously announced, Ocean Biomedical, Inc. (NASDAQ: OCEA) celebrates the discovery of...
Innovation Pharmaceuticals Visits BeaMed; New StingRay Laser System for Epilepsy and Brain Tumors Moving Toward FDA Submission
WAKEFIELD, MA, Feb. 23, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire – Innovation Pharmaceuticals (OTCQB:IPIX) (“the Company”), a clinical stage biopharmaceutical...
Patent Application Published for PharmAla Biotech’s MDMA Analogs
Patent covers 6 novel compositions of matter, which PharmAla has been studying in preclinical testing for over a yearVANCOUVER, British...
BioAtla Announces FDA Clearance of Investigational New Drug Application for BA3182, a CAB-EpCAMxCAB-CD3 Bispecific T-Cell Engager for the Treatment of Advanced Adenocarcinoma
Following the IND clearance, the Company is advancing into a Phase 1 clinical studyPotentially addressing most common subtypes of adenocarcinoma...
Baudax Bio Reports 2022 Fourth Quarter and Annual Financial Results and Provides Business Update
Company Focuses on Development of Neuromuscular Blocking Agents Phase II Randomized Trial for BX1000 Initiated, Positive Interim Results Announced; Completion...
Madrigal Pharmaceuticals Provides Corporate Updates and Reports 2022 Fourth Quarter and Full Year Financial Results
Positive Phase 3 MAESTRO-NASH study results reported in December 2022 position Madrigal for a resmetirom new drug application filing in...